Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer Posted by Saúl Morales Rodriguéz in biotech/medical Jun 52024 Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024. Read more | >
